Abstract
Obesity has been described as a ' public health time-bomb' . In 2005, the World
Health Organization estimated that approximately 400 million individuals are
obese. Prevalence of obesity is rising worryingly in many countries, despite
campaigns emphasizing the link between being overweight and contracting
diabetes. This new report - Anti-Obesity Treatments 2009-2024 - explains
those trends in commercial terms. In two of the largest national markets for
anti-obesity treatments - the US and UK - over 20% of the population are
seriously overweight. Obesity is a major risk factor in a number of other
serious disorders, particularly diabetes and heart disease. Importantly, the
financial burden of obesity and its associated conditions - both direct and
indirect costs - are vast. Obesity is a serious, chronic condition with an
emerging market for therapeutic products, as we show in this study. High
socioeconomic costs and increasing prevalence are inspiring government
initiatives to deal with the problem, with obesity becoming one of the most
prominent global health concerns worldwide. Visiongain recognizes the
contribution of drugs in this important emerging market, as diet and exercise
are frequently not successful alone. We predict that new classes of drugs will
invigorate the market - driving total sales in the next decade. In this report
you will find out about those treatments, especially their sales potential.
Drug sales in the global anti-obesity market approached $2bn in 2008, with the
market to grow substantially over the forecast period 2009-2024. This growth
will be associated with a complex environment of label changes,
reformulations, patent expiry, OTC switching and new product launches. Those
opportunities are highlighted by the extensive R&D pipeline, crowded with
novel therapies to improve treatment of obesity. Which new treatments have
blockbuster potential? Our report will cover this and other important matters.
Importantly, too, prevalence of obesity is rising in Latin America, India and
China in particular - important pharmaceutical markets covered here.
Anti-Obesity Treatments 2009-2024 provides detailed analysis of the global
anti-obesity market, with comprehensive sales forecasting. With a rigorous
study of sources, including commercial databases, company reports, industry
news and first-hand interviews with experts in the obesity sector, this report
is a unique opportunity to discover how your company can develop over the next
5 years. The result is a comprehensive market- and industry-based report with
detailed analyses and informed opinion that you will not find anywhere else.
Anti-Obesity Treatments 2009-2024 highlights the following essential aspects of the market:
- A global forecast for the anti-obesity drugs market with comprehensive
discussions
- Sales forecasts for the current-leading drugs
- Assessment of new drug releases, both therapeutically and commercially
- Sales forecasts for the leading national anti-obesity markets, as well as
for emerging national markets
- Discussion of strengths, weakness, opportunities and threats (SWOT) facing
major stakeholders in the anti-obesity drug sector
- Extensive analysis of pipeline developments, including avenues for future
research
- Discussion of current un-met and under-met needs in the anti-obesity
market, revealing both therapeutic needs and commercial opportunities.
Why you should buy this report:
- To receive a comprehensive analysis of the prospects for anti-obesity
therapies from 2009-2024, including predicted revenues, growth rates and other
key metrics
- To identify key pipeline developments, the most promising therapy classes
and potential methods of treatment
- To discover the important drivers and restraints for the global
anti-obesity market, including factors affecting leading national markets
- To find out where the global anti-obesity market is heading - both
technologically and commercially - from the present onwards.
This report is essential reading for anyone in the pharmaceutical and
healthcare sector with an interest in obesity and related conditions.
Purchasing this report will help you to recognise those important market
opportunities and understand the possibilities there.
Table of Contents
1. Executive Summary: Anti-Obesity Treatments 2009-2024
2. An Introduction to Obesity and Its Treatment
- 2.1 What is Obesity?
- 2.1.1 Fat is a Necessary Component of the Body
- 2.1.2 Obesity is a Chronic Disease
- 2.1.3 Body Weight is Dependent upon Several Factors
- 2.2 How is Obesity Measured?
- 2.2.1 Weight-for-Height Tables
- 2.2.2 Waist Circumference
- 2.2.3 Body Mass Index (BMI)
- 2.3 How Serious is the Problem?
- 2.3.1 Prevalence
- 2.3.2 Risk Factors of Other Diseases (Co-Morbidities)
- 2.3.3 Economic Costs
- 2.4 Historical Causes and Lifestyle Changes
- 2.4.1 Urbanisation, Modernisation and Economic Development
- 2.4.2 Developed Countries and in Developing Nations
- 2.5 Factors Causing Obesity
- 2.5.1 Lifestyle, Environment and Diet
- 2.5.2 Behaviour
- 2.5.3 Psychological Factors
- 2.5.4 Genetics
- 2.5.5 Antecedent Illnesses and Treatments
- 2.5.6 Other Causes
- 2.6 Treatment of Obesity
- 2.6.1 Lifestyle and Behavioural Changes
- 2.6.2 Unapproved Drugs
- 2.6.3 Alternative Therapies
- 2.6.4 Pharmacotherapy
- 2.6.5 Surgical Options
- 2.6.6 Drugs have a Role in the Treatment of Obesity.
- 2.7 Pharmacotherapy in the Treatment of Obesity
- 2.7.1 Lipase Inhibitors
- 2.7.2 Anorectic Drugs
- 2.7.3 Off-Label Use of Drugs
- 2.8 Need for Future Development in the Treatment of Obesity
- 2.8.1 Unmet Needs and Market Potential
3. The World Market for Anti-Obesity Drugs, 2009-2024
- 3.1 The Current Anti-Obesity Market Climate - a Potential Blockbuster
Market
- 3.2 Leading Companies in the Anti-Obesity Market
- 3.3 Market History and the Current Situation
- 3.3.1 The Effect of Pondimin, Redux and Public Opinion on the
Anti-Obesity Market
- 3.3.2 Rimonabant and other Cannabinoid Receptor Antagonists
- 3.3.3 Phentermine
- 3.4 Total Anti-Obesity Market Forecast 2009-2024
- 3.4.1 Market Growth in 2009-2024
- 3.4.2 Drugs after 2012
- 3.5 Xenical Forecast 2009-2024
- 3.5.1 Will Generic Erosion Drive Down Xenical' s Sales?
- 3.5.2 Competition Increases with New Releases
- 3.5.3 Will Xenical be Driven Out by Newer Rivals?
- 3.6 Reductil/Meridia Forecast 2009-2024
- 3.6.1 How Will Competition Affect Sales?
- 3.6.2 Expiry of Patents in 2013
- 3.7 Alli Forecast 2009-2024
- 3.7.1 Early Launch-Stocking
- 3.7.2 European Launch
- 3.7.3 Is Alli Failing to Distinguish Itself?
- 3.8 Dinintel Forecast 2009-2024
- 3.8.1 Will the Rapidly Evolving Anti-Obesity Market Will Leave Dinintel
Behind?
- 3.9 Total Other Drugs Forecast 2009-2024
- 3.9.1 Generic Competitors
- 3.9.2 New Drug: Contrave (Orexigen)
- 3.9.3 New Drug: Lorcaserin (Arena)
- 3.9.4 New Drug: Qnexa (Vivus)
- 3.9.5 New Drug: Liraglutide (Novo Nordisk)
- 3.9.6 New Drug: Empatic/Excalia (Orexigen)
- 3.10 Market Summary
- 3.10.1 New Drugs and the Market
- 3.10.2 Lack of Innovation and the Market Opportunities?
- 3.10.3 The Problems with Anorectic Drugs
- 3.10.4 The Problems with Lipase Inhibitors
- 3.10.5 The Future of Anti-Obesity Treatments
4. Anti-Obesity Treatments - SWOT Analysis
- 4.1 Strengths
- 4.1.1 Long-Term Therapy with Anti-Obesity Drugs
- 4.1.2 Prospects of Multiple Indications for Anti-Obesity Drugs
- 4.1.3 Off-Label Potential and Competition
- 4.1.4 The Anti-Obesity Market is Ready to be Revolutionised
- 4.1.5 Failure of Rimonabant Leaves Vacuum in the Market
- 4.1.6 New Drugs May Not Fill the Entirety of Customer Needs
- 4.2 Weaknesses
- 4.2.1 Limited Efficacy
- 4.2.2 Undesirable Side-Effects Limit Market Potential of Anti-Obesity
Medications
- 4.2.3 Increased Competition by both Impending New Releases and Generic
Competitors
- 4.2.4 Regulatory Hurdles have Become Stricter - Companies Pay the Price
- 4.2.5 Pharmacotherapy Will Never be the First Line of Treatment?
- 4.3 Opportunities
- 4.3.1 Rising Prevalence Drives Market Potential
- 4.3.2 Unmet Market Needs - Can Drugs Solve this Problem?
- 4.3.3 A Safe and Effective Anti-Obesity Treatment has Applications in
Both the Clinical and Cosmetic Sectors
- 4.3.4 How the Changing Government Agenda and the High Economic Costs of
Obesity Will Drive Growth in the Anti-Obesity Market
- 4.3.5 Diet and Exercise May be the Mainstay Treatment, but this Approach
is not Always Effective
- 4.4 Threats
- 4.4.1 Reimbursement May Continue to be a Limiting Factor
- 4.4.2 Long-Term Safety Issues Continue to Stunt Growth
- 4.4.3 Opinion of Both the Public and Prescribing Bodies is Heavily
Dependent upon Individual Drug Successes and Success of the Market as a Whole
- 4.4.4 Will Healthier Lifestyles Limit the Current Need for Anti-Obesity
Drugs?
5. Pipeline Developments in Anti-Obesity Treatments
- 5.1 Treatments in Phase III
- 5.1.1 Lorcaserin
- 5.1.2 Qnexa
- 5.1.3 Contrave
- 5.1.4 Cetilistat
- 5.2 Treatments in Phase II
- 5.2.1 Empatic/Excalia
- 5.2.2 Liraglutide
- 5.2.3 Obinepitide
- 5.2.4 Solabegron
- 5.2.5 Tesofensine
- 5.2.6 Velneperit
- 5.2.7 Histalean
- 5.2.8 Sodium Tungstate
- 5.2.9 Serglifozin Etabonate
- 5.2.10 Pramlintide & Metreleptin
- 5.2.11 Hoodia gordonii Extract
- 5.2.12 MTP Inhibitor
- 5.2.13 TM 30339
- 5.2.14 SLx 4090
- 5.2.15 MK 0493
- 5.2.16 KRP 204
- 5.2.17 FM VP4
- 5.2.18 AZD 2207
- 5.2.19 CE 326597
- 5.3 Treatments in Phase I
- 5.3.1 Trodusquemine
- 5.3.2 THCV
- 5.3.3 Oral PYY3-36
- 5.3.4 ATHX 105
- 5.3.5 AZD 1175
- 5.3.6 AZD 1656
- 5.3.7 BVT 74316
- 5.3.8 CP 404
- 5.3.9 KD 3010
- 5.3.10 PRX 07034
- 5.3.11 PSN 602
- 5.3.12 TKS 1225
- 5.3.13 V 24343
- 5.3.14 TTP 435
- 5.4 Other Promising Pipeline Developments
- 5.4.1 Melanotan
- 5.4.2 Increasing Mitochondrial Activity to Increase Energy Expenditure
- 5.4.3 Inhibiting the Creation of Fat Stores after Gut Absorption
6. Obesity in the Leading World Markets
- 6.1 The Total Market for Anti-Obesity Treatments
- 6.1.1 Drug Development Will Drive the Market
- 6.2 US Anti-Obesity Market Forecast 2009-2024
- 6.2.1 Patent Expiries and New Drug Releases Will Create a Turbulent
Market
- 6.2.2 Will The Market Show Uninhibited Growth During the Forecast Period?
- 6.3 Mexico Anti-Obesity Market Forecast 2009-2024
- 6.3.1 The Health Care System Currently Limits Treatment Accessibility
- 6.3.2 Prevalence of Obesity Driving the Market
- 6.4 Brazil Anti-Obesity Market Forecast 2009-2024
- 6.4.1 Increasing Prevalence Will Force an Increase in Sales over the
Forecast Period
- 6.5 UK Anti-Obesity Market Forecast 2009-2024
- 6.5.1 Lagging Sales Will Turn to Positive Growth in the Early Forecast
Period
- 6.5.2 Government Agenda Will Support Growth of Anti-Obesity Treatments
in the UK
- 6.6 South Korea Anti-Obesity Market Forecast 2009-2024
- 6.6.1 Government Agenda Will Maintain High Sales
- 6.7 Spain Anti-Obesity Market Forecast 2009-2024
- 6.7.1 New Drug Releases and Patent Expiries
- 6.7.2 The Market Will Show Consistent Positive Growth
- 6.8 France Anti-Obesity Market Forecast 2009-2024
- 6.8.1 Reimbursement will Drive Sales
- 6.9 Total Other Countries Anti-Obesity Market Forecast 2009-2024
- 6.9.1 Total Other Countries Sales
- 6.9.2 The Impact of Emerging Markets
- 6.9.3 Emerging Market: India
- 6.9.4 Emerging Market: China
7. Experts' Views on the Main Issues in the Treatment of Obesity
- 7.1 An Interview with Dr. Tyrberg from The Burnham Institute Diabetes and
Obesity Research Centre
- 7.1.1 The Effect of Anti-Obesity Drugs on the Obese Population
- 7.1.2 The Cause-Effect Relationship between Diet, Obesity and Type 2
Diabetes
- 7.1.3 Off-Label Indications and Diabetes Treatments Used to Treat Obesity
- 7.1.4 Obesity as a Lifestyle Disease?
- 7.1.5 The Future of Anti-Obesity Treatments and the Role Diet and
Exercise Will Play
- 7.1.6 The Role of Pharmaceutical Companies, Ethics and the Cosmetic Use
of Anti-Obesity Treatments
- 7.1.7 Unmet Medical Needs in the Treatment of Obesity
- 7.1.8 The Future of the Anti-Obesity Market
- 7.2 Commentaries and Views from Other Experts in the Field
- 7.2.1 The Most Important Unmet Medical Needs in the Treatment of Obesity
- 7.2.2 The Future of Anti-Obesity Treatment
- 7.2.3 Funding of Anti-Obesity Treatments
- 7.2.4 The Anti-Obesity Market in Developing Nations
- 7.2.5 Concluding Thoughts
8 .Conclusions
- 8.1 Obesity is a Chronic Disease with Serious Health Implications
- 8.2 The Prevalence and Economic Costs of Obesity
- 8.3 The Modern Lifestyle has Contributed Significantly to Obesity
- 8.4 Obesity is Caused by a Complex Interplay of Factors
- 8.5 Obesity Treatments and the Role of Pharmaceuticals
- 8.6 The Unmet Needs and Market Potential for Anti-Obesity Treatments
- 8.7 The Anti-Obesity Market Will Expand from 2009-2024
- 8.8 The Main Drivers and Restraints of the Anti-Obesity Market
- 8.9 Geographical Overview of the Anti-Obesity Market
- 8.10 Outlook for the Future
Appendices
- Appendix 1: Conditions Associated with Obesity
- Appendix 2: Bariatric Surgery Options
- Appendix 3: About visiongain
- Appendix 4: Visiongain Report Evaluation Form
List of Tables
- Table 2.1 - BMI Classification Bands
- Table 2.2 - Obesity Prevalence Amongst US Adults 1991-2007
- Table 3.1 - Leading Anti-Obesity Drugs in Sales ($m), Market Share (%) and
Growth (%), 2007
- Table 3.2 - Leading Companies for Anti-Obesity Drugs in Sales ($m) and
Market Share (%), 2007
- Table 3.3 -Total Anti-Obesity Market Forecast in Sales ($m) and Growth
(%), 2009-2024
- Table 3.4 - Total Anti-Obesity Market CAGR Values (%), 2009-2024
- Table 3.5 - Xenical Forecast in Sales ($m) and Growth (%), 2009-2024
- Table 3.6 - Xenical CAGR Values (%), 2009-2024
- Table 3.7 - Reductil/Meridia Forecast in Sales ($m) and Growth (%),
2009-2024
- Table 3.8 - Reductil/Meridia CAGR Values (%), 2009-2024
- Table 3.9 - Alli Forecast in Sales ($m) and Growth (%), 2009-2024
- Table 3.10 - Alli CAGR Values (%), 2009-2024
- Table 3.11 - Dinintel Forecast in Sales ($m) and Growth (%), 2009-2024
- Table 3.12 - Dinintel CAGR Values (%), 2009-2024
- Table 3.13 - Total Other Drugs Forecast in Sales ($m) and Growth (%),
2009-2024
- Table 3.14 - Total Others Drugs CAGR Values (%), 2009-2024
- Table 4.1 - SWOT Chart of the Anti-Obesity Market, 2009-2024
- Table 5.1 -The Anti-Obesity Pipeline 2009
- Table 6.1 - US Anti-Obesity Market Forecast in Sales ($m) and Growth (%),
2009-2024
- Table 6.2 - US Anti-Obesity Market CAGR Values (%), 2009-2024
- Table 6.3 - Mexico Anti-Obesity Market Forecast in Sales ($m) and Growth
(%), 2009-2024
- Table 6.4 - Mexico Anti-Obesity Market CAGR Values (%), 2009-2024
- Table 6.5 - Brazil Anti-Obesity Market Forecast in Sales ($m) and Growth
(%), 2009-2024
- Table 6.6 - Brazil Anti-Obesity Market CAGR Values (%), 2009-2024
- Table 6.7 - UK Anti-Obesity Market Forecast in Sales ($m) and Growth (%),
2009-2024
- Table 6.8 - UK Anti-Obesity Market CAGR Values (%), 2009-2024
- Table 6.9 - South Korea Anti-Obesity Market Forecast in Sales ($m) and
Growth (%), 2009-2024
- Table 6.10 - South Korea Anti-Obesity Market CAGR Values (%), 2009-2024
- Table 6.11 - Spain Anti-Obesity Market Forecast in Sales ($m) and Growth
(%), 2009-2024
- Table 6.12 - Spain Anti-Obesity Market CAGR Values (%), 2009-2024
- Table 6.13 - France Anti-Obesity Market CAGR Values (%), 2009-2024
- Table 6.14 - France Anti-Obesity Market Forecast in Sales ($m) and Growth
(%), 2009-2024
- Table 6.15 - Total Other Countries Anti-Obesity Market Forecast in Sales
($m) and Growth (%), 2009-2024
- Table 6.16 - Total Other Countries Anti-Obesity Market CAGR Values (%),
2009-2024
- Table A2.1 - Bariatric Surgery Options
List of Figures
- Figure 2.1 - Obesity Prevalence Amongst US Adults 1991-2007
- Figure 3.1 - Leading Anti-Obesity Drugs Sales ($m), 2007
- Figure 3.2 - Leading Anti-Obesity Drugs Market Share (%), 2007
- Figure 3.3 - Leading Companies of Anti-Obesity Drugs Sales ($m), 2007
- Figure 3.4 - Leading Companies Anti-Obesity Market Share (%), 2007
- Figure 3.5 - Total Anti-Obesity Market Sales ($m), 2009-2024
- Figure 3.6 - Xenical Sales ($m), 2009-2024
- Figure 3.7 - Reductil/Meridia Sales ($m), 2009-2024
- Figure 3.8 - Alli Sales ($m), 2009-2024
- Figure 3.9 - Dinintel Sales ($m), 2009-2024
- Figure 3.10 - Total Other Drugs Sales ($m), 2009-2024
- Figure 3.11 - All Drugs Market Share (%), 2009-2024
- Figure 6.1 - Total Anti-Obesity Market Sales ($m), 2009-2024
- Figure 6.2 - US Anti-Obesity Market Forecast Sales ($m), 2009-2024
- Figure 6.3 - Mexico Anti-Obesity Market Forecast Sales ($m), 2009-2024
- Figure 6.4 - Brazil Anti-Obesity Market Forecast Sales ($m), 2009-2024
- Figure 6.5 - UK Anti-Obesity Market Forecast Sales ($m), 2009-2024
- Figure 6.6 - South Korea Anti-Obesity Market Forecast Sales ($m), 2009-2024
- Figure 6.7 - Spain Anti-Obesity Market Forecast Sales ($m), 2009-2024
- Figure 6.8 - France Anti-Obesity Market Forecast Sales ($m), 2009-2024
- Figure 6.9 - Total Other Countries Anti-Obesity Market Forecast Sales
($m), 2009-2024
- Figure 6.10 - Anti-Obesity Combined Country Forecast Sales ($m), 2009-2024
- Figure 6.11 - Anti-Obesity Market Country Market Share Forecast (%),
2009-2024
- Figure 8.1 - Total Anti-Obesity Market Sales ($m), 2009-2024
- Figure 8.2 - Anti-Obesity Drugs Forecast by Market Share (%), 2009-2024
- Figure 8.3 - Anti-Obesity Combined Country Forecast Sales ($m), 2009-2024
- Figure 8.4 - Anti-Obesity Market Country Market Share Forecast, 2009-2024
Companies Listed
- 7TM Pharma
- Abbott
- Ache Laboratories
- Actavis
- Alizyme
- American Home Products
- Amylin
- Arena
- AstraZeneca
- Athersys
- Barcelona University
- Bayer
- Biovitrum
- Bristol-Myers Squibb
- Clinuvel
- Compellis
- Council for Scientific and Industrial Research
- Duke University
- Eli Lilly
- EMEA
- Emisphere
- EMS
- Epix
- FDA
- Forbes Medi-Tech
- Gate Pharmaceuticals
- Genaera
- GlaxoSmithKline
- Graceway Pharma
- GW Pharmaceuticals
- Han Wha
- Hanmi
- Inova Pharma
- Johnson & Johnson
- Kalypsys
- Kissei
- Kyorin
- Louisiana State University
- Medley
- Merck & Co.
- NeuroSearch
- Novartis
- Novo Nordisk
- Nycomed Pharma
- OBEcure
- Orexigen
- OSI Pharmaceuticals
- Pfizer
- Phytopharm
- Roche
- Sanofi-Aventis
- Shionogi
- Sirtris Pharmaceuticals
- Solvay
- Surface Logix
- Takeda
- Teva
- The Burnham Institute
- Transition
- TransTech
- URL Pharma
- Vernalis
- Vivus
- Wyeth Pharmaceuticals
|
相關報告
|
